Atomwise
- Denzil Bernard
Denzil Bernard is an experienced Director CADD at Atomwise, with a background as a Principal Scientist and Senior Scientist. Previously, Denzil worked as a Research Specialist at the University of Michigan, where they focused on the development of novel small molecule anti-cancer therapeutics and identification of new therapeutic targets. Denzil's expertise includes lead identification through various methods such as virtual screening, docking, and chemoinformatics, as well as lead optimization through rational structure-based design. With a PhD in Pharmaceutical Science from the University of Maryland Baltimore, Denzil has a strong educational background in pharmacy and a proven track record in medicinal chemistry and biochemistry.
Location
San Francisco, United States
Links
Org chart
Upgrade to view 4 reports
Offices
Atomwise
3 followers
Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. They've partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals.
Ad